Tumor Necrosis Factor Receptor Superfamily Member 8 / CD30 (TNFRSF8) Antibody (FITC)

Background

TNFRSF8 (Tumor Necrosis Factor Receptor Superfamily Member 8), also known as CD30, is a cell surface receptor belonging to the tumor necrosis factor receptor (TNFR) superfamily. This family is composed of receptors that play critical roles in modulating immune responses, inflammation, and apoptosis. CD30 is primarily expressed on activated T and B cells, and its expression is upregulated in certain immune-related diseases and cancers, particularly Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). It has emerged as a significant target in cancer immunotherapy and as a diagnostic marker for lymphoma. The receptor is a hallmark of classical Hodgkin lymphoma (cHL) and ALCL due to its overexpression on malignant cells. Beyond cancer, CD30 has implications in the regulation of immune homeostasis, playing a role in T-cell activation, differentiation, and proliferation. Dysregulation of CD30 signaling can lead to chronic inflammation and the development of autoimmune disorders, making it an essential molecule of interest in both oncology and immunology.